THE_DIABETIC_BOOT_COMPANY - Accounts


Company Registration No. 07171606 (England and Wales)
THE DIABETIC BOOT COMPANY LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019
PAGES FOR FILING WITH REGISTRAR
THE DIABETIC BOOT COMPANY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 9
THE DIABETIC BOOT COMPANY LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2019
2019-12-31
- 1 -
2019
2018
Notes
£
£
£
£
Fixed assets
Tangible assets
3
11,996
21,614
Investments
4
84
84
12,080
21,698
Current assets
Stocks
172,696
438,441
Debtors
5
189,734
54,106
Cash at bank and in hand
199,451
9,776
561,881
502,323
Creditors: amounts falling due within one year
6
(7,312,052)
(5,829,604)
Net current liabilities
(6,750,171)
(5,327,281)
Total assets less current liabilities
(6,738,091)
(5,305,583)
Capital and reserves
Called up share capital
606
606
Share premium account
4,873,664
4,873,664
Equity reserve
1,267,978
709,092
Warrant reserve
385,054
385,054
Profit and loss reserves
(13,265,393)
(11,273,999)
Total equity
(6,738,091)
(5,305,583)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 7 August 2020 and are signed on its behalf by:
A M Chow
Director
Company Registration No. 07171606
THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019
- 2 -
1
Accounting policies
Company information

The Diabetic Boot Company Limited is a private company limited by shares incorporated in England and Wales. The registered office is 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

Based on the latest trading expectations and associated cash flow forecasts of the Company, there are currently insufficient secured financial resources available to enable the Company to continue trading for the next 12 months and there are also loans that will become due for repayment.

 

The directors are currently in the process of exploring the options for additional funding. The directors are confident that they would be able to secure sufficient additional funding, extend the terms of the convertible loan notes and that ongoing interim funding will be available in the meantime, particularly given the receipt of interim funding to date. It is on this basis, the directors consider that the Company will be able to meet their liabilities as they fall due for a period of at least 12 months from the date of approval of these financial statements and have therefore prepared the accounts on a going concern basis. However, the directors recognise that obtaining this additional funding and extending the terms of existing funding cannot be guaranteed and this is considered to be a material uncertainty that may cast significant doubt over the Company’s ability to continue as a going concern.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
1
Accounting policies
(Continued)
- 3 -
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
Between 10% and 20% straight line
Computers
50% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
1
Accounting policies
(Continued)
- 4 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
1
Accounting policies
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Compound instruments

The component parts of compound instruments issued by the company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished upon conversion or at the instrument's maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in equity net of income tax effects and is not subsequently remeasured.

1.12
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
1
Accounting policies
(Continued)
- 6 -
1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2019
2018
Number
Number
Total
4
5
3
Tangible fixed assets
Plant and equipment
Computers
Total
£
£
£
Cost
At 1 January 2019
42,319
8,147
50,466
Additions
-
1,269
1,269
At 31 December 2019
42,319
9,416
51,735
Depreciation and impairment
At 1 January 2019
24,869
3,983
28,852
Depreciation charged in the year
8,885
2,002
10,887
At 31 December 2019
33,754
5,985
39,739
Carrying amount
At 31 December 2019
8,565
3,431
11,996
At 31 December 2018
17,450
4,164
21,614
4
Fixed asset investments
2019
2018
£
£
Shares in group undertakings and participating interests
84
84
THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
4
Fixed asset investments
(Continued)
- 7 -
Movements in fixed asset investments
Shares in group undertakings
£
Cost or valuation
At 1 January 2019 & 31 December 2019
84
Carrying amount
At 31 December 2019
84
At 31 December 2018
84
5
Debtors
2019
2018
Amounts falling due within one year:
£
£
Trade debtors
6,501
2,265
Other debtors
183,233
51,841
189,734
54,106
6
Creditors: amounts falling due within one year
2019
2018
Notes
£
£
Convertible loans
7
4,942,033
4,260,919
Trade creditors
45,630
33,182
Taxation and social security
7,232
6,525
Other creditors
2,317,157
1,528,978
7,312,052
5,829,604
THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
- 8 -
7
Convertible loan notes
2019
2018
£
£
Liability component of convertible loan notes
4,942,033
4,260,919

During the year, convertible loan notes with a nominal value of £1,240,000 (Series 3) (2018 - £260,000 (Series 2) and £1,018,606 (Series 3)) were issued by the company.

 

The convertible loan notes (Series 1 and 2) were redeemable on 17 November 2018 and (Series 3) were redeemable on 20 December 2019. They incur interest charges at either 7% (Series 1) or 10% (Series 2 and 3) per annum.

 

The loans have a convertible option which automatically converts the debt into either Senior debt on a fund raising event or Ordinary shares upon a share sale where control of the company changes or upon a listing. The conversion price is the lower of £15 per share or a 15% discount to the price paid per share upon the conversion event.

 

The net proceeds received from the issue of the convertible loan notes have been split between the financial liability element and an equity component, representing the fair value of the embedded option to convert the financial liability into equity.

 

The liability component is measured at amortised cost, and the difference between the carrying amount of the liability at the date of issue and the amount reported in the Balance Sheet represents the effective interest rate less interest paid to that date.

 

The equity component of the convertible loan notes has been credited to the equity reserve.

 

The directors in establishing a fair value for the consideration paid for the equity element of convertible loan notes were required to make an assumption in arriving at the valuation of the loan notes without the conversion option. The key estimation made was the discount factor of 20% to apply to the future cash flows in arriving at the fair value of the loan notes without the conversion option.

 

The loan notes are secured by fixed and floating charges over the assets of the company.

8
Share-based payment transactions
Number of share options
2019
2018
Number
Number
Outstanding at 1 January 2019 and 31 December 2019
10,000.00
12,000.00
Exercisable at 31 December 2019
10,000.00
12,000.00

The weighted average share price and exercise price at the date of exercise for the share options was £13.37.

The options vested on the date of grant which was 22 September 2015 and will lapse at the latest on 22 September 2025.

 

THE DIABETIC BOOT COMPANY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019
- 9 -
9
Warrant reserve

The warrant reserve, which is a distributable reserve, reflects the price paid for warrants issued in conjunction with ordinary share subscriptions. The price is established through recognised fair value pricing techniques set out in previous financial statements

10
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

The senior statutory auditor was Alison Richardson.
The auditor was Richardsons.
11
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2019
2018
£
£
14,388
7,967
2019-12-312019-01-01false07 August 2020CCH SoftwareCCH Accounts Production 2020.200No description of principal activityThis audit opinion is unqualifiedA M ChowT A NicoletteD Blackman071716062019-01-012019-12-31071716062019-12-31071716062018-12-3107171606core:PlantMachinery2019-12-3107171606core:ComputerEquipment2019-12-3107171606core:PlantMachinery2018-12-3107171606core:ComputerEquipment2018-12-3107171606core:CurrentFinancialInstrumentscore:WithinOneYear2019-12-3107171606core:CurrentFinancialInstrumentscore:WithinOneYear2018-12-3107171606core:CurrentFinancialInstruments2019-12-3107171606core:CurrentFinancialInstruments2018-12-3107171606core:ShareCapital2019-12-3107171606core:ShareCapital2018-12-3107171606core:SharePremium2019-12-3107171606core:SharePremium2018-12-3107171606core:OtherReservesSubtotal2019-12-3107171606core:OtherReservesSubtotal2018-12-3107171606core:OtherMiscellaneousReserve2019-12-3107171606core:OtherMiscellaneousReserve2018-12-3107171606core:RetainedEarningsAccumulatedLosses2019-12-3107171606core:RetainedEarningsAccumulatedLosses2018-12-3107171606bus:Director12019-01-012019-12-3107171606core:PlantMachinery2019-01-012019-12-3107171606core:ComputerEquipment2019-01-012019-12-31071716062018-01-012018-12-3107171606core:PlantMachinery2018-12-3107171606core:ComputerEquipment2018-12-31071716062018-12-3107171606core:WithinOneYear2019-12-3107171606core:WithinOneYear2018-12-31071716062017-12-3107171606bus:PrivateLimitedCompanyLtd2019-01-012019-12-3107171606bus:SmallCompaniesRegimeForAccounts2019-01-012019-12-3107171606bus:FRS1022019-01-012019-12-3107171606bus:Audited2019-01-012019-12-3107171606bus:Director22019-01-012019-12-3107171606bus:Director32019-01-012019-12-3107171606bus:FullAccounts2019-01-012019-12-31xbrli:purexbrli:sharesiso4217:GBP